ACC 2015: Edwards, Medtronic lock horns with positive next-gen TAVI data
This article was originally published in Clinica
Executive Summary
The rivalry between the two leading firms in the transcatheter aortic valve implantation (TAVI) market, Edwards Lifesciences and Medtronic, looks set to continue, with both reporting positive results with their next-generation devices. The data were presented at the American College of Cardiology (ACC) meeting, being held in San Diego, California on 14-16 March.